Final results of a phase I study of idelalisib, a selective inhibitor of phosphatidylinositol 3-kinase P110δ (PI3Kδ), in patients with relapsed or refractory mantle cell lymphoma (MCL)

被引：0
|
作者：
Spurgeon, Stephen Edward Forbes
Wagner-Johnston, Nina D.
Furman, Richard R.
Flinn, Ian
Coutre, Steven E.
Brown, Jennifer R.
Benson, Don M.
Byrd, John C.
Leonard, John
Peterman, Sissy
Johnson, David Michael
Gu, Jessie
Dansey, Roger D.
Godfrey, Wayne R.
Kahl, Brad S.
机构：
[1] Oregon Hlth & Sci Univ, Portland, OR 97201 USA
[2] Washington Univ, Sch Med, St Louis, MO USA
[3] Weill Cornell Med Coll, New York, NY USA
[4] Sarah Cannon Res Inst, Nashville, TN USA
[5] Stanford Canc Inst, Stanford, CA USA
[6] Dana Farber Canc Inst, Boston, MA 02115 USA
[7] Ohio State Univ, Columbus, OH 43210 USA
[8] Gilead Sci Inc, Seattle, WA USA
[9] Univ Wisconsin, Carbone Canc Ctr, Madison, WI USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2013年 / 31卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
8519
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A phase 1 study of the PI3Kδ inhibitor idelalisib in patients with relapsed/refractory mantle cell lymphoma (MCL)
    Kahl, Brad S.
    Spurgeon, Stephen E.
    Furman, Richard R.
    Flinn, Ian W.
    Coutre, Steven E.
    Brown, Jennifer R.
    Benson, Don M.
    Byrd, John C.
    Peterman, Sissy
    Cho, Yoonjin
    Yu, Albert
    Godfrey, Wayne R.
    Wagner-Johnston, Nina D.
    BLOOD, 2014, 123 (22) : 3398 - 3405
  • [2] Idelalisib, an inhibitor of phosphatidylinositol 3-kinase p110δ, for relapsed/refractory chronic lymphocytic leukemia
    Brown, Jennifer R.
    Byrd, John C.
    Coutre, Steven E.
    Benson, Don M.
    Flinn, Ian W.
    Wagner-Johnston, Nina D.
    Spurgeon, Stephen E.
    Kahl, Brad S.
    Bello, Celeste
    Webb, Heather K.
    Johnson, Dave M.
    Peterman, Sissy
    Li, Daniel
    Jahn, Thomas M.
    Lannutti, Brian J.
    Ulrich, Roger G.
    Yu, Albert S.
    Miller, Langdon L.
    Furman, Richard R.
    BLOOD, 2014, 123 (22) : 3390 - 3397
  • [3] Final results of a phase I study of idelalisib, a selective inhibitor of PI3Kδ, in patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL)
    Benson, Don M.
    Kahl, Brad S.
    Furman, Richard R.
    Brown, Jennifer R.
    Wagner-Johnston, Nina D.
    Coutre, Steven E.
    Spurgeon, Stephen Edward Forbes
    Byrd, John C.
    Leonard, John
    Peterman, Sissy
    Johnson, David Michael
    Cho, Yoonjin
    Dansey, Roger D.
    Godfrey, Wayne R.
    Flinn, Ian
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [4] Final results of a phase I study of idelalisib (GSE1101) a selective inhibitor of PI3Kδ, in patients with relapsed or refractory CLL.
    Brown, Jennifer R.
    Furman, Richard R.
    Flinn, Ian
    Coutre, Steven E.
    Wagner-Johnston, Nina D.
    Kahl, Brad S.
    Spurgeon, Stephen Edward Forbes
    Benson, Don M.
    Peterman, Sissy
    Johnson, David Michael
    Li, Daniel
    Dansey, Roger D.
    Jahn, Thomas Michael
    Byrd, John C.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [5] Phase II study of idelalisib, a selective inhibitor of PI3Kδ, for relapsed/refractory classical Hodgkin lymphoma
    Gopal, A. K.
    Fanale, M. A.
    Moskowitz, C. H.
    Shustov, A. R.
    Mitra, S.
    Ye, W.
    Younes, A.
    Moskowitz, A. J.
    ANNALS OF ONCOLOGY, 2017, 28 (05) : 1057 - 1063
  • [6] Puquitinib mesylate, an inhibitor of phosphatidylinositol 3-kinase p110δ, for treating relapsed or refractory non Hodgkin's lymphoma
    Yang, Hang
    Wang, Yu
    Zhan, Jing
    Xia, Yi
    Sun, Peng
    Bi, Xi-Wen
    Liu, Pan-Pan
    Li, Zhi-Ming
    Li, Su
    Zou, Ben-Yan
    Jiang, Wen-Qi
    ONCOTARGET, 2015, 6 (41) : 44049 - 44056
  • [7] Copanlisib: An Intravenous Phosphatidylinositol 3-Kinase (PI3K) Inhibitor for the Treatment of Relapsed Follicular Lymphoma
    Eltantawy, Adel
    Vallejos, Ximena
    Sebea, Elrodia
    Evans, Kirsten
    ANNALS OF PHARMACOTHERAPY, 2019, 53 (09) : 954 - 958
  • [8] Phase 2a study of the phosphatidylinositol-3-kinase (PI3K) inhibitor copanlisib in patients with relapsed/refractory, indolent or aggressive lymphoma
    Dreyling, M. H.
    Morschhauser, F.
    Bouabdallah, K.
    Cunningham, D.
    Bron, D.
    Linton, K.
    Assouline, S.
    Verhoef, G.
    Thieblemont, C.
    Vitolo, U.
    Garcia-Vargas, J.
    Gorbatchevsky, I
    Neves, M.
    Grunert, J.
    Hiemeyer, F.
    Childs, B. H.
    Zinzani, P. L.
    ONCOLOGY RESEARCH AND TREATMENT, 2016, 39 : 310 - 310
  • [9] PHASE 2A STUDY OF THE PHOSPHATIDYLINOSITOL-3-KINASE (PI3K) INHIBITOR COPANLISIB IN PATIENTS WITH RELAPSED/REFRACTORY, INDOLENT OR AGGRESSIVE LYMPHOMA
    Dreyling, M.
    Morschhauser, F.
    Bouabdallah, K.
    Cunningham, D.
    Bron, D.
    Linton, K.
    Assouline, S.
    Verhoef, G.
    Thieblemont, C.
    Vitolo, U.
    Garcia-Vargas, J.
    Gorbatchevsky, I.
    Neves, M.
    Grunert, J.
    Hiemeyer, F.
    Childs, B. H.
    Zinzani, P. L.
    HAEMATOLOGICA, 2016, 101 : 104 - 104
  • [10] Evidence of Clinical Activity in a Phase I Study of CAL-101, An Oral P110Δ Isoform-Selective Inhibitor of Phosphatidylinositol 3-Kinase, in Patients with Relapsed or Refractory B-Cell Malignancies
    Flinn, Ian W.
    Byrd, John C.
    Furman, Richard R.
    Brown, Jennifer R.
    Benson, Don M.
    Coutre, Steven E.
    Kahl, Brad S.
    Smith, B. Douglas
    Wagner-Johnston, Nina D.
    Spurgeon, Stephen E.
    Giese, Neill A.
    Yu, Albert S.
    BLOOD, 2009, 114 (22) : 380 - 380
12345